epithalon vs vilon

epithalon (C-tier) vs vilon (D-tier). mechanism, trials, evidence boundaries, dosing literature. side-by-side reference.

epithalon · tier C

russian longevity peptide. one lab. one cohort. the lifespan claims have never been replicated.

Russian longevity peptide. one lab (Khavinson). one human cohort (2003). the lifespan claims have never been replicated.

Russia Khavinson '80s · half-life minutes in plasma; downstream effects on melatonin signaling persist longer · focus

vilon · tier D

two amino acids from a russian lab, lysine joined to glutamic acid, sold on an anti-ageing claim. nobody has registered a trial of it in any registry checked, the three human papers state no sample size, and the strongest animal study reports more tumours.

two amino acids sold to slow ageing and to hold tumours back, and both claims come back weaker than the label. the one lifespan experiment that compared them head to head gave the survival gain to the sibling pineal peptide and reported no survival figure for this one. on tumours, three animal models favour it and the best-refereed study reports more mammary cancer. the human immune claim has never been tested at all.

0 registered trials · ClinicalTrials.gov + WHO ICTRP · half-life not characterised; no published human pharmacokinetic study was located · focus

at a glance

• epithalon: tier C · Russia Khavinson '80s
• vilon: tier D · 0 registered trials · ClinicalTrials.gov + WHO ICTRP

reptides grades the research record and cites the literature behind every call. research reference only; not medical advice.